Post the presentation at the 2025 JPMorgan Healthcare Conference by BridgeBio (BBIO), JPMorgan analyst Anupam Rama says the firm was “VERY encouraged” by initial Attruby metrics and notes that there are plenty of clinical catalysts on the horizon for 2025. The firm was not expecting a pre-announcement on Q4 sales for Attruby, but points out that the company presented initial market metrics from the Attruby launch. JPMorgan reiterates an Overweight rating on the shares based on its positive commercial outlook for Attruby as well as the underappreciated pipeline levers looking towards 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio announces commercial progress, pipeline updates
- 3 Best Stocks to Buy Now, 12/24/2024, According to Top Analysts
- BridgeBio price target raised to $50 from $45 at Evercore ISI
- BridgeBio receives positive CHMP opinion for acoramidis for ATTR-CM treatment
- BridgeBio participates in a conference call with Cantor Fitzgerald